Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with five trillion compounds in less than 3 months.
-
Branche
-
Biotechnologieforschung
-
Größe
-
11–50 Beschäftigte
-
Hauptsitz
-
Bethesda, Maryland
-
Art
-
Kapitalgesellschaft (AG, GmbH, UG etc.)
-
Gegründet
-
2017
-
Spezialgebiete
-
Rare diseases, neurodegenerative diseases, pharmacological chaperones, lysosomal storage disorders und oncology